Release Date: September 5, 2023 
Expiration Date: September 5, 2024
Time to Complete: 0.25 hour

Lead Faculty

Daniel E. Soffer, MD, FNLA, FACP
President, National Lipid Association
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman School of Medicine
Philadelphia, PA

Contributing Faculty

Susan Halli Demeter, DNP, FNP-BC, CLS, FNLA, FPCNA
President, Preventive Cardiovascular Nurses Association
Assistant Professor of Medicine
Heart Health & Performance Program
Lipid Clinic
Mayo Clinic Arizona
Scottsdale, AZ

Program Overview

Managing low-density lipoprotein cholesterol (LDL-C) levels in patients with comorbidities can be challenging. This Case Consult offers strategies to manage the care of a patient with peripheral arterial disease and prior myocardial infarction, as well as recent clinical trial data to support clinical decision-making.

Target Audience

This activity has been designed to address the educational needs of cardiologists, cardiology nurses, lipid specialists, and primary care clinicians, including internists, family medicine physicians, pharmacists, nurses, nurse practitioners, PAs, and dietitians. It may also benefit other healthcare providers who manage patients with hypercholesterolemia.

Type of Activity

Internet Activity - Enduring
Knowledge

Learning Objectives

Upon completion of this activity, participants should be able to:

• Describe clinical trial designs and the associated efficacy and safety data for newer and emerging nonstatin low-density lipoprotein cholesterol (LDL-C)–lowering therapies
• Distinguish among the unique drug characteristics of newer and emerging nonstatin LDL-C therapies that may impact clinical decision-making
• Discuss the role of team-based care and shared decision-making in applying the guideline to various clinical practice settings

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at the end of this activity. The deadline to claim credit is September 5, 2024.

For assistance regarding credit, please contact cme@lipid.org.

For pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

*IMPORTANT* 
Pharmacists MUST request credit before September 5, 2024. Credit requested after this date will be subject to a fee.

Disclosure of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Accreditation

CREDIT DESIGNATION 

CME/CE credit provided by the National Lipid Association 
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement 

The National Lipid Association designates this enduring internet activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

 Pharmacist Accreditation Statement

Universal Activity Number JA0007192-9999-23-034-H01-P
This activity has been approved for .25 contact hour (0.025 CEU) of the Accreditation Council for Pharmacy Education.

Nursing

The maximum number of hours awarded for this CE activity 0.25 contact hours.
For the advanced practice nurse, pharmacotherapy contact hours will be determined on your certificate.

Educational Provider

This activity is provided by the National Lipid Association. Paradigm Medical Communications, LLC is the educational partner.    

Instructions for Participation 

To receive a CME certificate of participation, you should:

• Follow instructions to register or log in with your professional information and complete the preactivity assessment.
• View the online activity in its entirety.
• Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have 3 opportunities to successfully complete the posttest.

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

There is no fee required for participation in this activity.

Hardware/Software Requirements

This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosures

Susan Halli Demeter, DNP, NFO-BC, CLS, FNLA, FPCNA 
Has no relevant financial relationships to disclose.

Daniel E. Soffer, MD, FNLA, FACP
Author: Novartis AG
Contracted Research: Amgen Inc; Amryt Pharma plc; AstraZeneca; Ionis Pharmaceuticals, Inc; Novartis AG; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Verve Therapeutics, Inc.
Consultant: Akcea Therapeutics, Inc.; Novartis AG; Regeneron Pharmaceuticals Inc

Joyce L. Ross, MNLA, MSN, CRNP, FNLA
Consultant: Amgen Inc; Kaneka Medical America LLC
Speaker: Amarin Pharmaceuticals Ireland Limited; Amgen Inc; Kaneka Medical America LLC; MEDS; Medscape, LLC 

The National Lipid Association and Paradigm Medical Communications, LLC staff members have no financial relationships to disclose. 

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.  

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Terms of Use and Privacy Policy
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information.
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. 

Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com. 

© 2023 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.